<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160275</url>
  </required_header>
  <id_info>
    <org_study_id>NL43469.018.13</org_study_id>
    <nct_id>NCT02160275</nct_id>
  </id_info>
  <brief_title>Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format</brief_title>
  <acronym>APPEL4</acronym>
  <official_title>Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, APPEL 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J.H. DeVries</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In previous studies, we tested the feasibility of a bi-hormonal closed loop system. This
      system for automated control of blood glucose in patients with type 1 diabetes was tested in
      the clinical research center as well as at the home of the patients. Glucose control with
      automated closed loop control was comparable to patient-managed open loop control.

      The closed loop system has been further developed and miniaturized (from backpack to
      smartphone size) in order to interfere as little as possible with daily patient life. The aim
      of this trial is to assess the efficacy of the new prototype at the home of the patient. It
      is hypothesized that the closed loop system provides better glucose control than standard
      open loop therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sensor glucose concentration</measure>
    <time_frame>Day 2-4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of time spent in each glycemic category</measure>
    <time_frame>Day 2-4</time_frame>
    <description>Glycemic categories:
Low glucose (&lt;3.9 mmol/l and ≥ 3.3 mmol/l)
Very low glucose (&lt;3.3 mmol/l and ≥ 2.8 mmol/l)
Dangerously low glucose (&lt;2.8 mmol/l)
High glucose (&gt; 10 mmol/l and ≤ 13.9 mmol/l)
Very high glucose (&gt; 13.9 mmol/l and ≤ 22.2 mmol/)
Dangerously high glucose (&gt; 22.2 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events in each glycemic category</measure>
    <time_frame>Day 2-4</time_frame>
    <description>Glycemic categories:
Low glucose (&lt;3.9 mmol/l and ≥ 3.3 mmol/l)
Very low glucose (&lt;3.3 mmol/l and ≥ 2.8 mmol/l)
Dangerously low glucose (&lt;2.8 mmol/l)
High glucose (&gt; 10 mmol/l and ≤ 13.9 mmol/l)
Very high glucose (&gt; 13.9 mmol/l and ≤ 22.2 mmol/)
Dangerously high glucose (&gt; 22.2 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of carbohydrate-treated hypoglycemic events</measure>
    <time_frame>Day 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of time spent in euglycemia (≥ 3.9 mmol/l and ≤ 10 mmol/l)</measure>
    <time_frame>Day 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>Day 2-4</time_frame>
    <description>Calculated as Interquartile Range (IQR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sensor glucose concentration during specific periods</measure>
    <time_frame>Day 2-4</time_frame>
    <description>Periods:
Day
Night
Postprandial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute relative difference between sensor values and self-monitored blood glucose values</measure>
    <time_frame>Day 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Day 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Day 2-4</time_frame>
    <description>Acceleration measured with a tri-axial accelerometer. The physical activity parameter is calculated as the magnitude of the total acceleration vector (square root of the sum of the squared axes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose concentration per day</measure>
    <time_frame>Day 1-4</time_frame>
    <description>Intervention arm (closed loop) only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time that the control algorithm is inactive</measure>
    <time_frame>Day 1-4</time_frame>
    <description>Intervention arm (closed loop) only</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Insulin use</measure>
    <time_frame>Day 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon use</measure>
    <time_frame>Day 1-4</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Open Loop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Closed Loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Pancreas (Inreda Diabetic BV)</intervention_name>
    <description>Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype</description>
    <arm_group_label>Closed Loop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump therapy</intervention_name>
    <description>Patients' own insulin pump with fast-acting insulin analog</description>
    <arm_group_label>Open Loop</arm_group_label>
    <other_name>Continuous subcutaneous insulin infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with diabetes mellitus type 1

          -  Treated with insulin pump therapy for a minimum of 6 months

          -  Age between 18 and 75 years

          -  Willing and able to sign informed consent

        Exclusion Criteria:

          -  Impaired awareness of hypoglycemia (score ≥ 4) according to Gold and/or Clarke
             questionnaire

          -  BMI &gt; 35 kg/m2

          -  HbA1c &gt; 97 mmol/mol (=11.0 %)

          -  Use of heparin, coumarin derivatives or oral corticosteroids

          -  Skin condition prohibiting needle insertion

          -  Pregnancy and/or breastfeeding

          -  Living alone during the closed loop period (the patient may ask someone to stay over
             temporarily)

          -  Any condition that the local investigator feels would have interfere with trial
             participation or the evaluation of the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hans DeVries, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.H. DeVries</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Artificial pancreas</keyword>
  <keyword>Bi-hormonal closed loop</keyword>
  <keyword>Diabetes Type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

